These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 23458727

  • 1. Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors.
    Wang C, Shi W, Cai L, Lu L, Wang Q, Zhang T, Li J, Zhang Z, Wang K, Xu L, Jiang X, Jiang S, Liu K.
    J Med Chem; 2013 Mar 28; 56(6):2527-39. PubMed ID: 23458727
    [Abstract] [Full Text] [Related]

  • 2. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C, Shi W, Cai L, Lu L, Yu F, Wang Q, Jiang X, Xu X, Wang K, Xu L, Jiang S, Liu K.
    J Antimicrob Chemother; 2014 Jun 28; 69(6):1537-45. PubMed ID: 24500189
    [Abstract] [Full Text] [Related]

  • 3. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
    He XY, Lu L, Qiu J, Zou P, Yu F, Jiang XK, Li L, Jiang S, Liu S, Xie L.
    Bioorg Med Chem; 2013 Dec 01; 21(23):7539-48. PubMed ID: 23673219
    [Abstract] [Full Text] [Related]

  • 4. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
    Shi W, Cai L, Lu L, Wang C, Wang K, Xu L, Zhang S, Han H, Jiang X, Zheng B, Jiang S, Liu K.
    Chem Commun (Camb); 2012 Dec 07; 48(94):11579-81. PubMed ID: 23093045
    [Abstract] [Full Text] [Related]

  • 5. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H, Qiu Z, Su Y, Yang L, He Y.
    AIDS; 2015 Jan 02; 29(1):13-21. PubMed ID: 25562490
    [Abstract] [Full Text] [Related]

  • 6. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y.
    FASEB J; 2013 Mar 02; 27(3):1203-13. PubMed ID: 23233535
    [Abstract] [Full Text] [Related]

  • 7. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
    An T, Ouyang W, Pan W, Guo D, Li J, Li L, Chen G, Yang J, Wu S, Tien P.
    Antiviral Res; 2012 Jun 02; 94(3):276-87. PubMed ID: 22426469
    [Abstract] [Full Text] [Related]

  • 8. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, Izumi K, Sakagami Y, Oishi S, Ohkubo T, Kobayashi Y, Otaka A, Fujii N, Matsuoka M.
    Int J Biochem Cell Biol; 2009 Apr 02; 41(4):891-9. PubMed ID: 18834950
    [Abstract] [Full Text] [Related]

  • 9. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.
    Biochemistry; 2007 Apr 10; 46(14):4360-9. PubMed ID: 17371053
    [Abstract] [Full Text] [Related]

  • 10. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M, Rucker J, Hoffman TL, Doms RW, Shai Y.
    Biochemistry; 1999 Aug 31; 38(35):11359-71. PubMed ID: 10471286
    [Abstract] [Full Text] [Related]

  • 11. Design and Biological Evaluation of m-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex.
    Meng G, Pu J, Li Y, Han A, Tian Y, Xu W, Zhang T, Li X, Lu L, Wang C, Jiang S, Liu K.
    J Med Chem; 2019 Oct 10; 62(19):8773-8783. PubMed ID: 31513410
    [Abstract] [Full Text] [Related]

  • 12. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
    He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q.
    Proc Natl Acad Sci U S A; 2008 Oct 21; 105(42):16332-7. PubMed ID: 18852475
    [Abstract] [Full Text] [Related]

  • 13. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
    Chong H, Yao X, Sun J, Qiu Z, Zhang M, Waltersperger S, Wang M, Cui S, He Y.
    J Biol Chem; 2012 Oct 05; 287(41):34558-68. PubMed ID: 22879603
    [Abstract] [Full Text] [Related]

  • 14. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
    Wang C, Lu L, Na H, Li X, Wang Q, Jiang X, Xu X, Yu F, Zhang T, Li J, Zhang Z, Zheng B, Liang G, Cai L, Jiang S, Liu K.
    J Med Chem; 2014 Sep 11; 57(17):7342-54. PubMed ID: 25156906
    [Abstract] [Full Text] [Related]

  • 15. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro.
    Pang W, Wang RR, Yang LM, Liu CM, Tien P, Zheng YT.
    Virology; 2008 Jul 20; 377(1):80-7. PubMed ID: 18499209
    [Abstract] [Full Text] [Related]

  • 16. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.
    Cell; 2007 Apr 20; 129(2):263-75. PubMed ID: 17448989
    [Abstract] [Full Text] [Related]

  • 17. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 18. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
    Dams G, Van Acker K, Gustin E, Vereycken I, Bunkens L, Holemans P, Smeulders L, Clayton R, Ohagen A, Hertogs K.
    J Biomol Screen; 2007 Sep 21; 12(6):865-74. PubMed ID: 17644771
    [Abstract] [Full Text] [Related]

  • 19. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B, Tian YS, Utachee P, Sapsutthipas S, Isarangkura-na-Ayuthaya P, Auwanit W, Takagi T, Ikuta K, Sawanpanyalert P, Kawashita N, Kameoka M.
    Virology; 2010 Sep 15; 405(1):157-64. PubMed ID: 20580393
    [Abstract] [Full Text] [Related]

  • 20. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
    Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y.
    PLoS One; 2012 Sep 15; 7(3):e32599. PubMed ID: 22403678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.